Emergent BioSolutions Inc. (0IGA.L)
| Previous close | 1.8500 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 19,429 |
| Market cap | 847,837 |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 2.9670 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...
Significant Recovery Noted as EBS Beats Analyst Estimates and Updates Full-Year Guidance
GlobeNewswireEmergent BioSolutions Reports First Quarter 2024 Financial Results
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significa
- Reuters
UPDATE 2-Emergent BioSolutions to lay off about 300 employees
Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as part of a restructuring plan. The company has been seeking to cut costs and pivot away from its contract manufacturing business due to sluggish demand and drive sales growth for its opioid overdose reversal drug Narcan and other branded drugs. Emergent said it will close its Baltimore, Bayview drug substance manufacturing facility and its Rockville, Maryland drug product facility.
